A major new review challenges the idea that a daily aspirin can reliably prevent bowel cancer in the general population. For years, aspirin has been floated as a simple, low-cost way to lower colorectal cancer risk. A new Cochrane review argues the reality is much less reassuring for people at average risk. In the trials [...]from SciTechDaily https://ift.tt/IcKo7Xq
